Home Medicine Distinct expression and prognostic value of MS4A in gastric cancer
Article Open Access

Distinct expression and prognostic value of MS4A in gastric cancer

  • Lei Sun , Yanli Zhang and Chao Zhang EMAIL logo
Published/Copyright: May 9, 2018
Download Article (PDF)
Open Medicine
From the journal Open Medicine Volume 13 Issue 1

Abstract

Gastric cancer has high malignancy and early metastasis, which lead to poor survival rate. In this study, we assessed the expressions and prognostic values of MS4A family, a newly recently discovered family, by two online dataset, GEPIA and Kaplan Meier-plotter. From these results eight members, MS4A2, MS4A6, MS4A7, MS4A8, MS4A14, MS4A15, TMEM176A and TMEM176B showed positive expression in gastric cancer or normal tissues, and these genes were screened for further analysis of prognostic values. We observed that low mRNA expressions of MS4A2, MS4A7, MS4A14, MS4A15, TMEM176A and TMEM176B were correlated with better overall survival (OS) in all gastric cancer patients, while high mRNA expression of MS4A6 was observed to be associated with good prognosis. MS4A8’s high mRNA level was correlated to better OS in diffuse gastric cancer patients. Further, we estimated prognostic values of MS4A family in gastric cancer patients with different clinic-pathological features, including clinical stages, differentiation level, lymph node status and HER2 status. Our results indicate that these eight MS4A members can estimate prognosis in patients with different pathological groups. In conclusion, MS4A family members are potential biomarkers, and may contribute to tumor progression in gastric cancer.

Keywords: Membrane-spanning 4-domains subfamily A; Gastric cancer; Prognosis; mRNA expression

1 Introduction

Gastric cancer is one of the most frequent malignant tumor and the second leading cause of mortality from any type of cancer worldwide [1]. Because of its high malignancy and early metastasis, the 5-year overall survival is only about 30% to 50%. Although the comprehensive treatment of gastric cancer with surgery, radiotherapy and chemotherapy is constantly updated, the overall survival rate is yet not significantly improved. There is still a lack of specific therapeutic targets and independent prognostic indicators [2]. Therefore, there is an urgent need to develop methods that can inhibit the invasion and metastasis of gastric cancer, as well as indicators that can independently guide the prognosis.

Membrane-spanning 4-domains subfamily A (MS4A) belongs to transmembrane proteins and contains at least 16 members in human [3]. MS4A family members are homologous in amino acid sequences with similar chromosome location and protein structure. These genes are mainly expressed in lymphocytes and hematopoietic cells, operating as cell surface signaling and intracellular adapter proteins [4]. In recent years, with the in-depth study of the MS4A family members, it has been observed that MS4A proteins show abnormal expression and fulfil diverse functions in multiple solid tumor tissues [5,6,7,8,9]. However, studies of MS4A in tumor are in the initial stage, and the role of MS4A in gastric cancer still remains unknown.

In the present study, we analyzed MS4A family expression levels in gastric cancer, and screened 8 members that showed positive expression to analyze their prognostic values in gastric cancer using an online dataset. Seven of them were confirmed to be potential prognostic markers in gastric cancer.

2 Methods

Expression and prognostic values of MS4As family were analyzed using two online dataset, Gene Expression Profiling Interactive Analysis (GEPIA) and Kaplan Meier-plotter dataset (http://kmplot.com/analysis/). GEPIA was an interactive web server for estimating the mRNA expression data from 9,736 tumors and 8,587 normal samples in the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) dataset projects [10]. The |Log2FC| cutoff of the expression of proposed biomarker was 1. All boxplot analysis used log2(TPM + 1) for log-scale.

Kaplan Meier-plotter database can analyze prognostic values of gene mRNA expression in breast, gastric, lung and ovarian cancer patients, and also miRNA expression in liver and breast cancer patients [11]. Samples with gene expression data and prognosis information used in Kaplan Meier-plotter dataset are downloaded from TCGA, EGA and GEO (Affymetrix microarrays only). The database is handled by a PostgreSQL server, which integrates gene expression and clinical data simultaneously. So far, a number of genes have been identified and validated by KM plotter in these four types of cancer [12,13,14,15]. In this on line dataset, clinical data from 876 gastric cancer patients including Lauren classification, clinical stage, differentiation, HER2 status and lymph node status were collected. The Affymetrix IDs of MS4As were entering into the web (http://kmplot.com/analysis/index.php?p=service&-cancer=gastric), and then data were compared through a Kaplan-Meier survival plot. The patient samples were split into two groups by median. The hazard ratio (HR) with 95% confidence intervals (95% CI) and P value were calculated by a PostgreSQL server. P < 0.05 was considered to be a significant difference.

3 Results

3.1 Differential expression of MS4As between tumor and normal tissues in gastric cancer

This study was set out with the aim of assessing MS4As prognosis values in gastric cancer. First, we excluded MS4A family members which were negative or nearly negative in gastric cancer tissues. An online tool, GEPIA which was based on TCGA and GTEx dataset for transcriptomic analysis, was used to investigate the mRNA expression level of MS4A family in gastric cancer [10]. Analysis results demonstrated that expressions of MS4A1, MS4A3, MS4A4, MS4A5, MS4A10, MS4A12, MS4A13 and MS4A18 were negative or nearly negative, while MS4A2, MS4A6, MS4A7, MS4A8, MS4A14, MS4A15, TMEM176A and TMEM176B expressions were positive in gastric cancer or paracancerous tissues. The results of these MS4A members’ expression are shown in Figure 1. From the boxplot, we confirmed that MS4A2 mRNA level decreased in gastric cancer tissues in cooperation to normal tissues (Fig. 1A). By contrast, MS4A6, MS4A7 and MS4A15 mRNA levels increased in gastric cancer tissues (Fig. 1B, C and F). Notably, TMEM176A and TMEM176B mRNA levels were observed to be up-regulated with statistical significance in gastric cancer tissues (Fig. 1G and H). Based on these data, eight members were screened for further prognostic value analysis.

Figure 1 Analysis of MS4A mRNA level in human gastric cancer. The red and gray boxes represent cancer and normal tissues respectively. Compared with the normal tissues, MS4A2 (A) mRNA level decreases, while MS4A6 (B), MS4A7 (C) and MS4A15 (F) mRNA levels increase in gastric cancer tissues. There were only slight differences in MS4A8 (D) and MS4A14 (E) between gastric normal and cancer tissues. Notably, TMEM176A (G) and TMEM176B (H) mRNA level increased in gastric cancer tissues with statistically significant. (*P<0.01)
Figure 1

Analysis of MS4A mRNA level in human gastric cancer. The red and gray boxes represent cancer and normal tissues respectively. Compared with the normal tissues, MS4A2 (A) mRNA level decreases, while MS4A6 (B), MS4A7 (C) and MS4A15 (F) mRNA levels increase in gastric cancer tissues. There were only slight differences in MS4A8 (D) and MS4A14 (E) between gastric normal and cancer tissues. Notably, TMEM176A (G) and TMEM176B (H) mRNA level increased in gastric cancer tissues with statistically significant. (*P<0.01)

Figure 2 Prognostic roles of MS4A are determined in www.kmplot.com. The desired Affymetrix IDs are valid: 207496_at (MS4A2), 219666_at (MS4A6), 223344_s_at (MS4A7), 224355_s_at (MS4A8), 229510_at (MS4A14), 1564194_a_at (MS4A15), 218345_at (TMEM176A), 220532_s_at (TMEM176B). Survival curves are plotted for all gastric cancer patients (n = 876). From this data, high mRNA expression of MS4A6 (B), or low mRNA expression of MS4A2 (A) or MS4A7 (C) or MS4A14 (E) or MS4A15 (F) or TMEM176A (G) or TMEM176B (H) were correlated with better OS.
Figure 2

Prognostic roles of MS4A are determined in www.kmplot.com. The desired Affymetrix IDs are valid: 207496_at (MS4A2), 219666_at (MS4A6), 223344_s_at (MS4A7), 224355_s_at (MS4A8), 229510_at (MS4A14), 1564194_a_at (MS4A15), 218345_at (TMEM176A), 220532_s_at (TMEM176B). Survival curves are plotted for all gastric cancer patients (n = 876). From this data, high mRNA expression of MS4A6 (B), or low mRNA expression of MS4A2 (A) or MS4A7 (C) or MS4A14 (E) or MS4A15 (F) or TMEM176A (G) or TMEM176B (H) were correlated with better OS.

3.2 Prognostic value of MS4A family in gastric cancer

Prognostic roles of eight screened MS4A family were determined in www.kmplot.com. The valid Affymetrix IDs are as follows: 207496_at (MS4A2), 219666_at (MS4A6), 223344_s_at (MS4A7), 224355_s_at (MS4A8), 229510_at (MS4A14), 1564194_a_at (MS4A15), 218345_at (TMEM176A), 220532_s_at (TMEM176B). Figure 1 represents a survival curves plotted for all patients with gastric cancer (n = 876). From this data, low mRNA expression of MS4A2 was correlated with better OS in all gastric cancer [HR = 1.23, 95% CI: (1.03-1.47), P = 0.025], as well as MS4A7 [HR = 1.33, 95% CI: (1.05-1.68), P = 0.019], MS4A14 [HR = 1.25, 95% CI: (1.25-1.92), P<0.0001], MS4A15 [HR = 1.28, 95% CI: (1.04-1.59), P = 0.022], TMEM176A [HR = 1.49, 95% CI: (1.24-1.78), P<0.0001] and TMEM176B [HR = 1.64, 95% CI: (1.37-1.96), P<0.0001]. High mRNA expression of MS4A6 was observed to be associated with a good prognosis [HR = 0.72, 95% CI: (0.61-0.85), P = 0.00014]. MS4A8’s high mRNA level was modestly correlated to better OS without statistical significance.

Furthermore, we estimated prognostic values of MS4As in gastric cancer patients with different Lauren classification, including intestinal, diffuse and mixed type. As shown in Figure 3, low MS4A2 mRNA level was associated with better OS in intestinal type gastric cancer patients [HR = 1.55, 95% CI: (1.12-2.14), P = 0.008], as well as MS4A7 [HR = 1.62, 95% CI: (1.12-2.33), P = 0.0092], MS4A14 [HR = 1.69, 95% CI: (1.17-2.43), P = 0.0048], MS4A15 [HR = 1.63, 95% CI: (1.13-2.35), P = 0.0088], TMEM176A [HR = 2.18, 95% CI: (1.57-3.03), P<0.0001] and TMEM176B [HR = 2.46, 95% CI: (1.72-3.51), P<0.0001]. Figure 4 shows the prognostic values of MS4As in diffuse type gastric cancer patients. From these data, patients with high MS4A2 [HR = 0.67, 95% CI: (0.47-0.94), P = 0.019] or MS4A8 [HR = 0.68, 95% CI: (0.47-0.99), P = 0.042] level show better OS, while patients with high MS4A14 [HR = 1.47, 95% CI: (1.02-2.13), P = 0.04] or TMEM176B [HR = 1.51, 95% CI: (1.08-2.13), P = 0.016] show poorer OS in diffuse gastric cancer.

Figure 3 Prognostic roles of MS4A in the intestinal gastric cancer. Survival curves are plotted for intestinal gastric cancer patients (n = 336). Patients with low MS4A2 (A) level show better OS in intestinal gastric cancer, as well as MS4A7 (B), MS4A14 (C), MS4A15 (D), TMEM176A (E) and TMEM176B (F).
Figure 3

Prognostic roles of MS4A in the intestinal gastric cancer. Survival curves are plotted for intestinal gastric cancer patients (n = 336). Patients with low MS4A2 (A) level show better OS in intestinal gastric cancer, as well as MS4A7 (B), MS4A14 (C), MS4A15 (D), TMEM176A (E) and TMEM176B (F).

Figure 4 Prognostic roles of MS4A in diffuse gastric cancer. Survival curves are plotted for diffuse gastric cancer patients (n = 248). Patients with high MS4A2 (A) or MS4A8 (B) level show better OS, while patients with high MS4A14 (C) or TMEM176B (D) show poorer OS in diffuse gastric cancer.
Figure 4

Prognostic roles of MS4A in diffuse gastric cancer. Survival curves are plotted for diffuse gastric cancer patients (n = 248). Patients with high MS4A2 (A) or MS4A8 (B) level show better OS, while patients with high MS4A14 (C) or TMEM176B (D) show poorer OS in diffuse gastric cancer.

3.3 Prognostic roles of MS4A family in gastric cancer patients with different pathological characteristics

Next, we estimated prognostic values of MS4As in gastric cancer patients with different pathological characteristics, including clinical stages, differentiation level, lymph node status and HER2 status. Table 1 shows the results of prognostic value analysis for gastric cancer patients with different clinical stages. From these data, low mRNA level of MS4A2 was only correlated with a good prognosis in stage 3 gastric cancer patients [HR = 1.41, 95% CI: (1.04-1.92), P = 0.027]. MS4A6’s high expression was correlated to better OS in stage 1 and 2 patients [stage 1: HR = 0.26, 95% CI: (0.09-0.77), P= 0.0091; stage 2: HR = 2.85, 95% CI: (1.12-7.25), P = 0.022]. MS4A7’s low mRNA level was associated with good prognosis in stage 1, 3 and 4 patients [stage 1: HR = 0.3, 95% CI: (0.1-0.91), P = 0.024; stage 3: HR = 0.6, 95% CI: (0.41-0.87), P = 0.0066; stage 4: HR = 1.71, 95% CI: (1.08-2.71), P = 0.02]. Low expression of MS4A14 was correlated to good prognosis in stage 1 and 4 patients [stage 1: HR = 0.28, 95% CI: (0.07-1.05), P = 0.046; stage 4: HR = 1.85, 95% CI: (1.19-2.88), P = 0.0058]. Low expression of MS4A15 was associated with better OS in stage 1, 3 and 4 patients [stage 1: HR = 7.96, 95% CI: (2.44-25.94), P<0.0001; stage 3: HR = 1.59, 95% CI: (1.07-2.37), P = 0.021; stage 4: HR = 1.59, 95% CI: (1.06-2.39), P = 0.023]. Low mRNA level of TMEM176A was observed to be associated with a good prognosis in stage 1 and 3 [stage 1: HR = 18.63, 95% CI: (2.46-141.27), P<0.0001; stage 3: HR = 2.15, 95% CI: (1.49-3.1), P<0.0001]. Low mRNA level of TMEM176B was observed to be correlated to better OS in all stages gastric cancer patients [stage 1: HR = 7.41, 95% CI: (2.1-26.11), P = 0.00026; stage 2: HR = 1.89, 95% CI: (1.03-3.46), P = 0.037; stage 3: HR = 1.89, 95% CI: (1.37-2.61), P<0.0001; stage 4: HR = 1.48, 95% CI: (1-2.17), P = 0.046.

Table 1

Correlation of MS4A mRNA level with clinical stages of gastric cancer patients.

MS4AClinical stagesCasesHR95% CIP
MS4A21690.490.17-1.410.18
21451.90.98-3.70.053
33191.411.04-1.920.027
41520.750.51-1.110.15
MS4A61690.260.09-0.770.0091
21452.851.12-7.250.022
33190.680.5-0.921.30E-02
41521.150.78-1.680.48
MS4A71690.30.1-0.910.024
21451.690.88-3.250.11
33190.60.41-0.870.0066
41521.711.08-2.710.02
MS4A81691.550.52-4.620.43
21451.310.69-2.480.41
33190.70.48-1.010.058
41520.740.46-1.190.21
MS4A141690.280.07-1.050.046
21451.660.89-3.120.11
33191.510.94-2.440.086
41521.851.19-2.880.0058
MS4A151697.962.44-25.94<0.0001
21450.670.34-1.310.24
33191.591.07-2.370.021
41521.591.06-2.390.023
TMEM176A16918.632.46-141.27<0.0001
21451.660.9-3.050.1
33192.151.49-3.1<0.0001
41521.390.94-2.060.094
TMEM176B1697.412.1-26.110.00026
21451.891.03-3.460.037
33191.891.37-2.61<0.0001
41521.481-2.170.046

Prognostic values of MS4As in different differentiation level are reported in Table 2. From these data, high MS4A2 expression was correlated to better OS in poorly differentiated gastric cancer patients [HR = 0.63, 95% CI: (0.4-0.97), P= 0.036]. High mRNA levels of MS4A14 [HR = 2.02, 95% CI: (1.04-3.92), P = 0.033] and TMEM176A [HR = 3.31, 95% CI: (1.37-7.98), P = 0.0048] were observed to be associated with a good prognosis in moderately differentiated patients. The rest members of MS4As were not associated with a prognosis in different differentiation level gastric cancer.

Table 2

Correlation of MS4A mRNA expression with different differentiation level of gastric cancer patients.

MS4ADifferentiationCasesHR95% CIP
poorly differentiated1660.630.4-0.970.036
MS4A2moderately differentiated670.510.23-1.110.085
poorly differentiated1660.760.5-1.170.21
MS4A6moderately differentiated671.570.81-3.060.18
poorly differentiated1660.70.43-1.160.17
MS4A7moderately differentiated671.850.95-3.620.067
poorly differentiated1660.720.43-1.220.22
MS4A8moderately differentiated671.270.65-2.470.49
poorly differentiated1661.320.8-2.170.27
MS4A14moderately differentiated672.021.04-3.920.033
poorly differentiated1661.380.83-2.30.22
MS4A15moderately differentiated671.330.69-2.560.39
poorly differentiated1660.720.47-1.110.13
TMEM176Amoderately differentiated673.311.37-7.980.0048
poorly differentiated1660.670.43-1.050.078
TMEM176Bmoderately differentiated671.840.92-3.670.079

Table 3 reports the prognostic values of MS4As in different lymph node status. High mRNA level of MS4A6 was observed to be associated with better OS in lymph node positive patients [HR = 1.37, 95% CI: (1.03-1.81), P = 0.028]. Low expressions of MS4A7 [HR = 1.45, 95% CI: (1.1-1.91), P = 0.0075], MS4A8 [HR = 0.69, 95% CI: (0.5-0.94), P = 0.018], MS4A14 [HR = 1.48, 95% CI: (1.14-1.93), P = 0.0036], TMEM176A [HR = 1.77, 95% CI: (1.35-2.31), P<0.0001] and TMEM176B [HR = 1.86, 95% CI: (1.43-2.41), P<0.0001] were correlated with a good prognosis in lymph node positive patients. High expressions of MS4A14 [HR = 2.6, 95% CI: (1.13-5.96), P = 0.019] and MS4A15 [HR = .45, 95% CI: (1.01-5.99), P = 0.042] were correlated with a good prognosis in lymph node negative patients.

Table 3

Correlation of MS4A mRNA level with different lymph node status of gastric cancer patients.

MS4ALymph node statusCasesHR95% CIP
MS4A2negative760.60.25-1.470.26
positive4370.860.65-1.120.26
MS4A6negative760.490.21-1.120.086
positive4371.371.03-1.810.028
MS4A7negative760.540.23-1.280.16
positive4371.451.1-1.910.0075
MS4A8negative762.010.68-5.930.2
positive4370.690.5-0.940.018
MS4A14negative762.61.13-5.960.019
positive4371.481.14-1.930.0036
MS4A15negative762.451.01-5.990.042
positive4371.250.93-1.670.13
TMEM176Anegative762.170.95-5.430.058
positive4371.771.35-2.31<0.0001
TMEM176Bnegative762.10.85-5.20.1
positive4371.861.43-2.41<0.0001

Prognostic values of MS4As in gastric cancer patients with different HER2 status are shown in Table 4. Low mRNA levels of MS4A2 [HR = 1.32, 95% CI: (1-1.74), P = 0.052], MS4A7 [HR = 1.96, 95% CI: (1.3-2.96), P = 0.0012], MS4A 14 [HR = 1.83, 95% CI: (1.16-2.91), P = 0.0087], MS4A 15 [HR = 1.5, 95% CI: (1.03-2.18), P = 0.032] and TMEM176B [HR = 0.62, 95% CI: (0.46-0.85), P = 0.003] were correlated to HER2 positive patients. Low mRNA expressions of MS4A14 [HR = 1.64, 95% CI: (1.26-2.14), P = 0.00019], MS4A15 [HR = 1.35, 95% CI: (1.04-1.76), P = 0.024], TMEM176A [HR = 1.55, 95% CI: (1.23-1.95), P = 0.00019] and TMEM176B [HR = 1.62, 95% CI: (1.29-2.03), P<0.0001] were correlated to HER2 negative patients. However, high expression of MS4A6 was found to be associated with better OS in HER2 negative patients [HR = 0.67, 95% CI: (0.53-0.84), P = 0.00063].

Table 4

Correlation of MS4A mRNA level with different HER2 status of gastric cancer patients.

MS4AHER2 statusCasesHR95% CIP
negative6411.250.98-1.60.076
MS4A2positive4251.321-1.740.052
negative6410.670.53-0.840.00063
MS4A6positive4250.840.65-1.090.19
negative6411.260.97-1.650.086
MS4A7positive4251.961.3-2.960.0012
negative6410.770.56-1.050.093
MS4A8positive4250.690.46-1.020.06
negative6411.641.26-2.140.00019
MS4A14positive4251.831.16-2.910.0087
negative6411.351.04-1.760.024
MS4A15positive4251.51.03-2.180.032
negative6411.551.23-1.950.00019
TMEM176Apositive4250.770.58-1.010.059
negative6411.621.29-2.03<0.0001
TMEM176Bpositive4250.620.46-0.850.003

4 Discussion

In human, the MS4A family has been identified to have at least 16 members, namely: MS4A1-8, MS4A10, MS4A12-15, MS4A18, TMEM176A and TMEM176B. Most of the MS4A family members have 4-transmembrane structures. TMEM176A and TMEM176B sharing 16% of amino acids and similar structure with MS4A are attributed to this family. This superfamily is mostly expressed in lymphoid tissues [16]. However, recent studies showed that some members are expressed in nonlymphoid tissues, and fulfil diverse functions, including kidney, lung, heart, liver, etc [17]. The first question in this study sought to determine which MS4A family members show positive expressions in gastric cancer or paracancerous tissues. Based on our results, we confirmed that MS4A2, MS4A6, MS4A7, MS4A 8, MS4A14, MS4A15, TMEM176A and TMEM176B were positively expressed in gastric cancer or paracancerous tissues. Notably, MS4A6, MS4A7, MS4A15, TMEM176A and TMEM176B were up-regulated in gastric cancer tissues in comparison to paracancerous tissues, while MS4A2 was down-regulated in gastric cancer tissues. The aberrant expressions of these genes suggested that they could contribute to the progression of gastric cancer.

The prognostic values of these genes in gastric cancer were assessed by Kaplan Meier-plotter dataset. These results confirmed the association between gene mRNA expressions with OS of patients with gastric cancer. From these data, low mRNA expressions of MS4A2, MS4A7, MS4A14, MS4A15, TMEM176A and TMEM176B were correlated with better OS in all gastric cancer patients, while high mRNA expression of MS4A6 was observed to be associated with a good prognosis. MS4A8’s high mRNA level was correlated to better OS in diffuse gastric cancer patients.

In 2017, Ly D, et al. analyzed the gene expression on microarray datasets of resected tumor samples from 128 early-stage non-small cell lung cancer (NSCLC) adenocarcinoma patients to gain insights into the immune networks that regulate and/or predict tumor progression. They prove that the expression of MS4A2 is an independent prognostic marker for early-stage lung cancer patient survival[18]. In our results, MS4A2 is also an independent prognostic marker in gastric cancer. MS4A7 (CFFM4) is an earlier discovered member in MS4A family. Gingras et al. proved that with the increase of monocyte differentiation the MS4A7 expression level increased significantly, suggesting that MS4A7 may be related to the differentiation of monocytes[19]. Several studies on MS4A8 revealed that this MS4A member shows abnormal expression in prostate and colon cancers, and contributes to the progression of prostate cancer [20,21]. Compared with other members of the MS4A family, TMEM176A and TMEM176B were reported more frequently in tumors[22,23]. The latest reports revealed TMEM176A to be frequently methylated in human esophageal squamous cell cancer (ESCC) and colorectal cancer. TMEM176A is considered to be a potential tumor suppressor in ESCC. The methylation of TMEM176A may serve as a diagnostic and prognostic marker in ESCC and colorectal cancer [24,25]. In breast cancer, lymphoma, skin cancer and liver cancer tissues, TMEM176A and TMEM176B expression levels show significant differences between cancer and normal tissues, suggesting that these two genes may be considered as biomarkers for the diagnosis of related tumors [23]. In the present study, we prove that MS4A7, TMEM176A and TMEM176B may serve as prognostic markers in gastric cancer. Interestingly, TMEM176A and TMEM176B are up-regulated in gastric cancer, and the high levels of TMEM176A and TMEM176B indicate a good prognosis, suggesting that these two genes may contribute to the progression of gastric cancer. Although the MS4A family plays an important role in intracellular calcium disturbance, cell differentiation, and regulation of tumor cell behavior, the role and mechanism of this family in gastric cancer have not been studied. Based on the literature search of MS4A family mechanism, we speculate that the high expression of MS4A in gastric cancer may be regulated by CDX2 (caudal type homeobox 2) or EVI1 (ecotropic viral integration site 1) [6,26]. These two genes are important transcription factors involved in the regulation of cell differentiation and proliferation in cells and have been reported to regulate the expression of MS4A family members in a variety of tumors, thereby affecting the biological behavior of tumor cells [27,28,29]. Moreover, MS4A7 promotes monocyte differentiation through the p38MAPK pathway in monocytic leukemia [19]. At present, there are few studies on the mechanism of action of the MS4A family, which will also be the focus of our research in the future.

In conclusion, our present study is focused on abnormal expressions and prognostic values of MS4A family in gastric cancer. The findings of our study suggested that eight MS4A family members show positive expression in gastric or gastric cancer tissues, and were found to be associated with a prognosis in gastric cancer. The results of further analysis with clinic-pathological features indicate that these eight MS4A family members can estimate a prognosis in patients with different pathological groups. MS4A family members are potential biomarkers of gastric cancer, and may contribute to tumor progression. However, there is yet no research on physiological significance of MS4A family in gastric cancer, the specific function and mechanism of which need to be further elucidated.

  1. Competing financial interests statement: The authors declare no competing financial interests.

    This article is the original article, no plagiarism and infringement of intellectual property rights of others; and this paper does not have a draft of multi cast, does not involve confidentiality, and without signed controversy

References

[1] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics, 2012. Ca A Cancer Journal for Clinicians 2015; 65: 8710.3322/caac.20107Search in Google Scholar PubMed

[2] Choi YY, Noh SH, Cheong JH. Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. Yonsei Medical Journal 2015; 56: 1177-118510.3349/ymj.2015.56.5.1177Search in Google Scholar PubMed PubMed Central

[3] Liang Y, Buckley TR, Tu L, Langdon SD, Tedder TF. Structural organization of the human MS4A gene cluster on Chromosome 11q12. Immunogenetics 2001; 53: 357-36810.1007/s002510100339Search in Google Scholar PubMed

[4] 贺理, Li H, 王晓春, Xiaochun W. Research progress in MS4A gene family and tumor. 肿瘤 2016; 36: 345-350Search in Google Scholar

[5] Kutok JL, Yang X, Folkerth R, Adra CN. Characterization of the expression of HTm4 (MS4A3), a cell cycle regulator, in human peripheral blood cells and normal and malignant tissues. Journal of Cellular & Molecular Medicine 2011; 15: 86-9310.1111/j.1582-4934.2009.00925.xSearch in Google Scholar PubMed PubMed Central

[6] Heller G, Rommer A, Steinleitner K, Etzler J, Hackl H, Heffeter P et al. EVI1 promotes tumor growth via transcriptional repression of MS4A3. Journal of Hematology & Oncology 2015; 8: 2810.1186/s13045-015-0124-6Search in Google Scholar PubMed PubMed Central

[7] Johnson NA, Boyle M, Bashashati A, Leach S, Brooks-Wilson A, Sehn LH et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 2009; 113: 377310.1182/blood-2008-09-177469Search in Google Scholar PubMed PubMed Central

[8] Koslowski M, Türeci Ö, Huber C, Sahin U. Selective activation of tumor growth-promoting Ca 2+ channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2. Molecular Cancer,8,1(2009-09-25) 2009; 8: 7710.1186/1476-4598-8-77Search in Google Scholar PubMed PubMed Central

[9] He L, Deng HY, X CW. Decreased expression of MS4A12 inhibits differentiation and predicts early stage survival in colon cancer. Neoplasma 2017; 64: 6510.4149/neo_2017_108Search in Google Scholar PubMed

[10] Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic acids research 201710.1093/nar/gkx247Search in Google Scholar PubMed PubMed Central

[11] Lánczky A, Nagy Á, Bottai G, Munkácsy G, Szabó A, Santarpia L et al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Research & Treatment 2016; 160: 43910.1007/s10549-016-4013-7Search in Google Scholar PubMed

[12] Ivanova L, Zandberga E, Siliņa K, Kalniņa Z, Ābols A, Endzeliņš E et al. Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells. Cancer Chemotherapy & Pharmacology 2015; 75: 235-24610.1007/s00280-014-2635-1Search in Google Scholar PubMed

[13] Zhou X, Teng L, Min W. Distinct prognostic values of four-Notch-receptor mRNA expression in ovarian cancer. Tumor Biology 2016; 37: 6979-698510.1007/s13277-015-4594-5Search in Google Scholar PubMed

[14] Li K, Guo X, Wang Z, Li X, Bu Y, Bai X et al. The prognostic roles of ALDH1 isoenzymes in gastric cancer. Oncotargets & Therapy 2016; 9: 340510.2147/OTT.S102314Search in Google Scholar PubMed PubMed Central

[15] Xiong J, Zhang X, Chen X, Wei Y, Lu D, Han Y et al. Prognostic roles of mRNA expression of notch receptors in non-small cell lung cancer. Oncotarget 2017; 8: 1315710.18632/oncotarget.14483Search in Google Scholar PubMed PubMed Central

[16] Eon KL, Leffler M, Mackay GA, Hulett MD. The MS4A family: Counting past 1, 2 & 3. Immunology & Cell Biology 2015; 9410.1038/icb.2015.48Search in Google Scholar PubMed

[17] Antúnez C, Boada M, González-Pérez A, Gayán J, Ramírez-Lorca R, Marín J et al. The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer’s disease. Genome Medicine,3,5(2011-05-31) 2011; 3: 3310.1186/gm249Search in Google Scholar PubMed PubMed Central

[18] Ly D, Zhu CQ, Cabanero M, Tsao MS, Zhang L. Role for high-affinity IgE receptor in prognosis of lung adenocarcinoma patients. Cancer Immunology Research 2017; 5: 82110.1158/2326-6066.CIR-16-0392Search in Google Scholar PubMed

[19] Gingras MC, Lapillonne H, Margolin JF. CFFM4: a new member of the CD20/FcepsilonRIbeta family. Immunogenetics 2001; 53: 468-47610.1007/s002510100345Search in Google Scholar PubMed

[20] Lin YE, Wan F, Shen X, Sun J, Yuanyuan QU, Bian X et al. The expression and clinical significance of MS4A8B in prostate cancer tissue. Journal of Clinical Urology 2013Search in Google Scholar

[21] Michel J, Schönhaar K, Schledzewski K, Gkaniatsou C, Sticht C, Kellert B et al. Identification of the novel differentiation marker MS4A8B and its murine homolog MS4A8A in colonic epithelial cells lost during neoplastic transformation in human colon. Cell Death & Disease 2013; 4: e46910.1038/cddis.2012.215Search in Google Scholar PubMed PubMed Central

[22] Blaveri E, Kelly F, Mallei A, Harris K, Taylor A, Reid J et al. Expression Profiling of a Genetic Animal Model of Depression Reveals Novel Molecular Pathways Underlying Depressive-Like Behaviours. Plos One 2010; 5: e1259610.1371/journal.pone.0012596Search in Google Scholar PubMed PubMed Central

[23] Cuajungco MP, Podevin W, Valluri VK, Bui Q, Nguyen VH, Taylor K. Abnormal accumulation of human transmembrane (TMEM)-176A and 176B proteins is associated with cancer pathology. Acta Histochemica 2012; 114: 70510.1016/j.acthis.2011.12.006Search in Google Scholar PubMed PubMed Central

[24] Wang Y, Zhang Y, Herman JG, Linghu E, Guo M. Epigenetic silencing of TMEM176A promotes esophageal squamous cell cancer development. Oncotarget 2017; 8: 70035-7004810.18632/oncotarget.19550Search in Google Scholar PubMed PubMed Central

[25] Gao D, Han Y, Yang Y, Herman JG, Linghu E, Zhan Q et al. Methylation of TMEM176A is an independent prognostic marker and is involved in human colorectal cancer development. Epigenetics 2017: 00-0010.1080/15592294.2017.1341027Search in Google Scholar PubMed PubMed Central

[26] Koslowski M, Türeci O, Huber C, Sahin U. Selective activation of tumor growth-promoting Ca2+ channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2. Molecular Cancer 2009; 8: 7710.1186/1476-4598-8-77Search in Google Scholar PubMed PubMed Central

[27] Silberg DG, Swain GP, Suh ER, Traber PG. Cdx1 and cdx2 expression during intestinal development. Gastroenterology 2000; 119: 961-97110.1053/gast.2000.18142Search in Google Scholar PubMed

[28] Niwa H, Toyooka Y, Shimosato D, Strumpf D, Takahashi K, Yagi R et al. Interaction between Oct3/4 and Cdx2 determines trophectoderm differentiation. Cell 2005; 123: 917-92910.1016/j.cell.2005.08.040Search in Google Scholar PubMed

[29] Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A et al. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. Embo Journal 2005; 24: 1976-198710.1038/sj.emboj.7600679Search in Google Scholar PubMed PubMed Central

Received: 2017-12-02
Accepted: 2018-03-15
Published Online: 2018-05-09

© 2018 Lei Sun et al., published by De Gruyter

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Articles in the same Issue

  1. Regular Articles
  2. Cleidocranial dysplasia-dental disorder treatment and audiology diagnosis
  3. A hybrid neural network – world cup optimization algorithm for melanoma detection
  4. Early administration of venovenous extracorporeal life support for status asthmaticus during anaesthetic induction: case report and literature review
  5. Assessment of maximal isometric hand grip strength in school-aged children
  6. Evaluation of a neurokinin-1 antagonist in preventing multiple-day cisplatin-induced nausea and vomiting
  7. Value of continuous video EEG and EEG responses to thermesthesia stimulation in prognosis evaluation of comatose patients after cardiopulmonary resuscitation
  8. Platelet-rich plasma protects HUVECs against oX-LDL-induced injury
  9. Pharmacoeconomics of three therapeutic schemes for anti-tuberculosis therapy induced liver injury in China
  10. Small-cell lung cancer presenting as fatal pulmonary hemorrhage
  11. Correlation of retinopathy of prematurity with bronchopulmonary dysplasia
  12. Prognosis of treatment outcomes by cognitive and physical scales
  13. The efficacy of radiofrequency hyperthermia combined with chemotherapy in the treatment of advanced ovarian cancer
  14. Arcuate Fasciculus in Autism Spectrum Disorder Toddlers with Language Regression
  15. Aesthetic dental procedures: legal and medico-legal implications
  16. Blood transfusion in children: the refusal of Jehovah’s Witness parents’
  17. Burnout among anesthetists and intensive care physicians
  18. Relationship of HS CRP and sacroiliac joint inflammation in undifferentiated spondyloarthritis
  19. Ethical and legal issues in gestational surrogacy
  20. Effects of arginine vasopressin on migration and respiratory burst activity in human leukocytes
  21. Associations of diabetic retinopathy with retinal neurodegeneration on the background of diabetes mellitus. Overview of recent medical studies with an assessment of the impact on healthcare systems
  22. Pituitary dysfunction from an unruptured ophthalmic internal carotid artery aneurysm with improved 2-year follow-up results: A case report
  23. Effectiveness of treatment with endostatin in combination with emcitabine, carboplatin, and gemcitabine in patients with advanced non-small cell lung cancer: a retrospective study
  24. Piercing and tattoos in adolescents: legal and medico-legal implications
  25. The central importance of information in cosmetic surgery and treatments
  26. Penile calciphylaxis in a patient with end-stage renal disease: a case report and review of the literature
  27. Serum CA72-4 as a biomarker in the diagnosis of colorectal cancer: A meta-analysis
  28. Association between uric acid and metabolic syndrome in elderly women
  29. Distinct expression and prognostic value of MS4A in gastric cancer
  30. MAPK pathway involved in epidermal terminal differentiation of normal human epidermal keratinocytes
  31. Association of central obesity with sex hormonebinding globulin: a cross-sectional study of 1166 Chinese men
  32. Successful endovascular therapy in an elderly patient with severe hemorrhage caused by traumatic injury
  33. Inflammatory biomarkers and risk of atherosclerotic cardiovascular disease
  34. Related factors of early mortality in young adults with cerebral hemorrhage
  35. Growth suppression of glioma cells using HDAC6 inhibitor, tubacin
  36. Post-stroke upper limb spasticity incidence for different cerebral infarction site
  37. The esophageal manometry with gas-perfused catheters
  38. MMP-2 and TIMP-2 in patients with heart failure and chronic kidney disease
  39. Genetic testing: ethical aspects
  40. Intervention for physician burnout: A systematic review
  41. The melanin-concentrating hormone system in human, rodent and avian brain
  42. Clinical effects of piribedil in adjuvant treatment of Parkinson’s Disease: A meta-analysis
  43. Identification of a novel BRAF Thr599dup mutation in lung adenocarcinoma
  44. Adrenal incidentaloma – diagnostic and treating problem – own experience
  45. Common illnesses in tropical Asia and significance of medical volunteering
  46. Genetic risk in insurance field
  47. Genetic testing and professional responsibility: the italian experience
  48. The mechanism of mitral regurgitant jets identified by 3-dimensional transesophageal echocardiography
  49. Control of blood pressure and cardiovascular outcomes in type 2 diabetes
  50. Pseudomesotheliomatous primary squamous cell lung carcinoma: The first case reported in Turkey and a review of the literature
  51. Diagnostic efficacy of serum 1,3-β-D-glucan for invasive fungal infection: An update meta-analysis based on 37 case or cohort studies
  52. GPER was associated with hypertension in post-menopausal women
  53. Metabolic activity of sulfate-reducing bacteria from rodents with colitis
  54. Association of miRNA122 & ADAM17 with lipids among hypertensives in Nigeria
  55. The efficacy and safety of enoxaparin: a meta-analysis
  56. Cuffed versus uncuffed endotracheal tubes in pediatrics: a meta-analysis
  57. Thresholding for medical image segmentation for cancer using fuzzy entropy with level set algorithm
  58. Sleep deprivation in Intensive Care Unit – systematic review
  59. Benefits of computed tomography in reducing mortality in emergency medicine
  60. Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
  61. Limits of professional competency in nurses working in Nicu
  62. MDA-19 suppresses progression of melanoma via inhibiting the PI3K/Akt pathway
  63. The effect of smoking on posttraumatic pseudoarthrosis healing after internal stabilization, treated with platelet rich plasma (PRP)
  64. Partial deletion of the long arm of chromosome 7: a case report
  65. Meta-analysis of PET/CT detect lymph nodes metastases of cervical cancer
  66. High Expression of NLRC5 is associated with prognosis of gastric cancer
  67. Is monitoring mean platelet volume necessary in breast cancer patients?
  68. Resectable single hepatic epithelioid hemangioendothelioma in the left lobe of the liver: a case report
  69. Epidemiological study of carbapenem-resistant Klebsiella pneumoniae
  70. The CCR5-Delta32 genetic polymorphism and HIV-1 infection susceptibility: a meta-analysis
  71. Phenotypic and molecular characterisation of Staphylococcus aureus with reduced vancomycin susceptibility derivated in vitro
  72. Preliminary results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions
  73. Analysis of patient satisfaction with emergency medical services
  74. Guillain-Barré syndrome and Low back pain: two cases and literature review
  75. HELLP syndrome complicated by pulmonary edema: a case report
  76. Pharmacokinetics of vancomycin in patients with different renal function levels
  77. Recurrent chronic subdural hematoma: Report of 13 cases
  78. Is awareness enough to bring patients to colorectal screening?
  79. Serum tumor marker carbohydrate antigen 125 levels and carotid atherosclerosis in patients with coronary artery disease
  80. Plastic treatment for giant pseudocyst after incisional hernia mesh repair: a case report and comprehensive literature review
  81. High expression levels of fascin-1 protein in human gliomas and its clinical relevance
  82. Thromboembolic complications following tissue plasminogen activator therapy in patients of acute ischemic stroke - Case report and possibility for detection of cardiac thrombi
  83. The effects of gastrointestinal function on the incidence of ventilator-associated pneumonia in critically ill patients
  84. A report of chronic intestinal pseudo-obstruction related to systemic lupus erythematosus
  85. Risk model in women with ovarian cancer without mutations
  86. Direct oral anticoagulants and travel-related venous thromboembolism
  87. How bispectral index compares to spectral entropy of the EEG and A-line ARX index in the same patient
  88. Henoch-schonlein purpura nephritis with renal interstitial lesions
  89. Cardiovascular risk estimated by UKPDS risk engine algorithm in diabetes
  90. CD5 and CD43 expression are associate with poor prognosis in DLBCL patients
  91. Combination of novoseven and feiba in hemophiliac patients with inhibitors
https://doi.org/10.1515/med-2018-0028
Keywords for this article
Membrane-spanning 4-domains subfamily A; Gastric cancer; Prognosis; mRNA expression
Creative Commons
BY-NC-ND 4.0

Articles in the same Issue

  1. Regular Articles
  2. Cleidocranial dysplasia-dental disorder treatment and audiology diagnosis
  3. A hybrid neural network – world cup optimization algorithm for melanoma detection
  4. Early administration of venovenous extracorporeal life support for status asthmaticus during anaesthetic induction: case report and literature review
  5. Assessment of maximal isometric hand grip strength in school-aged children
  6. Evaluation of a neurokinin-1 antagonist in preventing multiple-day cisplatin-induced nausea and vomiting
  7. Value of continuous video EEG and EEG responses to thermesthesia stimulation in prognosis evaluation of comatose patients after cardiopulmonary resuscitation
  8. Platelet-rich plasma protects HUVECs against oX-LDL-induced injury
  9. Pharmacoeconomics of three therapeutic schemes for anti-tuberculosis therapy induced liver injury in China
  10. Small-cell lung cancer presenting as fatal pulmonary hemorrhage
  11. Correlation of retinopathy of prematurity with bronchopulmonary dysplasia
  12. Prognosis of treatment outcomes by cognitive and physical scales
  13. The efficacy of radiofrequency hyperthermia combined with chemotherapy in the treatment of advanced ovarian cancer
  14. Arcuate Fasciculus in Autism Spectrum Disorder Toddlers with Language Regression
  15. Aesthetic dental procedures: legal and medico-legal implications
  16. Blood transfusion in children: the refusal of Jehovah’s Witness parents’
  17. Burnout among anesthetists and intensive care physicians
  18. Relationship of HS CRP and sacroiliac joint inflammation in undifferentiated spondyloarthritis
  19. Ethical and legal issues in gestational surrogacy
  20. Effects of arginine vasopressin on migration and respiratory burst activity in human leukocytes
  21. Associations of diabetic retinopathy with retinal neurodegeneration on the background of diabetes mellitus. Overview of recent medical studies with an assessment of the impact on healthcare systems
  22. Pituitary dysfunction from an unruptured ophthalmic internal carotid artery aneurysm with improved 2-year follow-up results: A case report
  23. Effectiveness of treatment with endostatin in combination with emcitabine, carboplatin, and gemcitabine in patients with advanced non-small cell lung cancer: a retrospective study
  24. Piercing and tattoos in adolescents: legal and medico-legal implications
  25. The central importance of information in cosmetic surgery and treatments
  26. Penile calciphylaxis in a patient with end-stage renal disease: a case report and review of the literature
  27. Serum CA72-4 as a biomarker in the diagnosis of colorectal cancer: A meta-analysis
  28. Association between uric acid and metabolic syndrome in elderly women
  29. Distinct expression and prognostic value of MS4A in gastric cancer
  30. MAPK pathway involved in epidermal terminal differentiation of normal human epidermal keratinocytes
  31. Association of central obesity with sex hormonebinding globulin: a cross-sectional study of 1166 Chinese men
  32. Successful endovascular therapy in an elderly patient with severe hemorrhage caused by traumatic injury
  33. Inflammatory biomarkers and risk of atherosclerotic cardiovascular disease
  34. Related factors of early mortality in young adults with cerebral hemorrhage
  35. Growth suppression of glioma cells using HDAC6 inhibitor, tubacin
  36. Post-stroke upper limb spasticity incidence for different cerebral infarction site
  37. The esophageal manometry with gas-perfused catheters
  38. MMP-2 and TIMP-2 in patients with heart failure and chronic kidney disease
  39. Genetic testing: ethical aspects
  40. Intervention for physician burnout: A systematic review
  41. The melanin-concentrating hormone system in human, rodent and avian brain
  42. Clinical effects of piribedil in adjuvant treatment of Parkinson’s Disease: A meta-analysis
  43. Identification of a novel BRAF Thr599dup mutation in lung adenocarcinoma
  44. Adrenal incidentaloma – diagnostic and treating problem – own experience
  45. Common illnesses in tropical Asia and significance of medical volunteering
  46. Genetic risk in insurance field
  47. Genetic testing and professional responsibility: the italian experience
  48. The mechanism of mitral regurgitant jets identified by 3-dimensional transesophageal echocardiography
  49. Control of blood pressure and cardiovascular outcomes in type 2 diabetes
  50. Pseudomesotheliomatous primary squamous cell lung carcinoma: The first case reported in Turkey and a review of the literature
  51. Diagnostic efficacy of serum 1,3-β-D-glucan for invasive fungal infection: An update meta-analysis based on 37 case or cohort studies
  52. GPER was associated with hypertension in post-menopausal women
  53. Metabolic activity of sulfate-reducing bacteria from rodents with colitis
  54. Association of miRNA122 & ADAM17 with lipids among hypertensives in Nigeria
  55. The efficacy and safety of enoxaparin: a meta-analysis
  56. Cuffed versus uncuffed endotracheal tubes in pediatrics: a meta-analysis
  57. Thresholding for medical image segmentation for cancer using fuzzy entropy with level set algorithm
  58. Sleep deprivation in Intensive Care Unit – systematic review
  59. Benefits of computed tomography in reducing mortality in emergency medicine
  60. Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
  61. Limits of professional competency in nurses working in Nicu
  62. MDA-19 suppresses progression of melanoma via inhibiting the PI3K/Akt pathway
  63. The effect of smoking on posttraumatic pseudoarthrosis healing after internal stabilization, treated with platelet rich plasma (PRP)
  64. Partial deletion of the long arm of chromosome 7: a case report
  65. Meta-analysis of PET/CT detect lymph nodes metastases of cervical cancer
  66. High Expression of NLRC5 is associated with prognosis of gastric cancer
  67. Is monitoring mean platelet volume necessary in breast cancer patients?
  68. Resectable single hepatic epithelioid hemangioendothelioma in the left lobe of the liver: a case report
  69. Epidemiological study of carbapenem-resistant Klebsiella pneumoniae
  70. The CCR5-Delta32 genetic polymorphism and HIV-1 infection susceptibility: a meta-analysis
  71. Phenotypic and molecular characterisation of Staphylococcus aureus with reduced vancomycin susceptibility derivated in vitro
  72. Preliminary results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions
  73. Analysis of patient satisfaction with emergency medical services
  74. Guillain-Barré syndrome and Low back pain: two cases and literature review
  75. HELLP syndrome complicated by pulmonary edema: a case report
  76. Pharmacokinetics of vancomycin in patients with different renal function levels
  77. Recurrent chronic subdural hematoma: Report of 13 cases
  78. Is awareness enough to bring patients to colorectal screening?
  79. Serum tumor marker carbohydrate antigen 125 levels and carotid atherosclerosis in patients with coronary artery disease
  80. Plastic treatment for giant pseudocyst after incisional hernia mesh repair: a case report and comprehensive literature review
  81. High expression levels of fascin-1 protein in human gliomas and its clinical relevance
  82. Thromboembolic complications following tissue plasminogen activator therapy in patients of acute ischemic stroke - Case report and possibility for detection of cardiac thrombi
  83. The effects of gastrointestinal function on the incidence of ventilator-associated pneumonia in critically ill patients
  84. A report of chronic intestinal pseudo-obstruction related to systemic lupus erythematosus
  85. Risk model in women with ovarian cancer without mutations
  86. Direct oral anticoagulants and travel-related venous thromboembolism
  87. How bispectral index compares to spectral entropy of the EEG and A-line ARX index in the same patient
  88. Henoch-schonlein purpura nephritis with renal interstitial lesions
  89. Cardiovascular risk estimated by UKPDS risk engine algorithm in diabetes
  90. CD5 and CD43 expression are associate with poor prognosis in DLBCL patients
  91. Combination of novoseven and feiba in hemophiliac patients with inhibitors
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Winner of the OpenAthens UX Award 2026
Winner of the OpenAthens UX Award 2026
Have an idea on how to improve our website?
Please write us.
© 2026 De Gruyter Brill
Downloaded on 10.3.2026 from https://www.degruyterbrill.com/document/doi/10.1515/med-2018-0028/html
Scroll to top button